Holocene Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.1M | Sell |
738,099
-1,512,944
| -67% | -$125M | 0.14% | 169 |
|
|
2025
Q4 | $192M | Sell |
2,251,043
-2,495,651
| -53% | -$205M | 0.4% | 66 |
|
|
2025
Q3 | $369M | Buy |
4,746,694
+42,717
| +0.9% | +$3.34M | 0.84% | 15 |
|
|
2025
Q2 | $368M | Buy |
4,703,977
+1,223,460
| +35% | +$91.2M | 0.9% | 18 |
|
|
2025
Q1 | $252M | Buy |
3,480,517
+1,070,432
| +44% | +$76.6M | 0.74% | 35 |
|
|
2024
Q4 | $178M | Sell |
2,410,085
-397,382
| -14% | -$27.8M | 0.57% | 44 |
|
|
2024
Q3 | $185M | Sell |
2,807,467
-54,194
| -2% | -$3.94M | 0.75% | 36 |
|
|
2024
Q2 | $264M | Sell |
2,861,661
-536,990
| -16% | -$47.6M | 1.1% | 15 |
|
|
2024
Q1 | $325M | Buy |
3,398,651
+2,517,704
| +286% | +$211M | 1.19% | 9 |
|
|
2023
Q4 | $67.2M | Buy |
880,947
+255,869
| +41% | +$17.8M | 0.26% | 124 |
|
|
2023
Q3 | $43.3M | Sell |
625,078
-1,893,208
| -75% | -$152M | 0.19% | 153 |
|
|
2023
Q2 | $238M | Sell |
2,518,286
-292,711
| -10% | -$25.4M | 1.01% | 16 |
|
|
2023
Q1 | $233M | Buy |
2,810,997
+178,802
| +7% | +$14.1M | 1.14% | 9 |
|
|
2022
Q4 | $196M | Sell |
2,632,195
-248,443
| -9% | -$19.1M | 1.2% | 8 |
|
|
2022
Q3 | $238M | Buy |
2,880,638
+975,520
| +51% | +$93.9M | 1.52% | 5 |
|
|
2022
Q2 | $181M | Sell |
1,905,118
-30,428
| -2% | -$3.15M | 1.09% | 10 |
|
|
2022
Q1 | $228M | Sell |
1,935,546
-23,740
| -1% | -$2.66M | 1.19% | 11 |
|
|
2021
Q4 | $254M | Buy |
1,959,286
+1,060,575
| +118% | +$124M | 1.32% | 10 |
|
|
2021
Q3 | $102M | Buy |
898,711
+146,476
| +19% | +$16.7M | 0.55% | 51 |
|
|
2021
Q2 | $77.9M | Buy |
+752,235
| New | +$70.9M | 0.44% | 79 |
|
|
2021
Q1 | – | Sell |
-255,866
| Closed | -$23.3M | – | 835 |
|
|
2020
Q4 | $23.3M | Sell |
255,866
-889,043
| -78% | -$73.7M | 0.15% | 190 |
|
|
2020
Q3 | $91.4M | Sell |
1,144,909
-354,120
| -24% | -$27.6M | 0.69% | 40 |
|
|
2020
Q2 | $104M | Buy |
1,499,029
+237,772
| +19% | +$16.9M | 0.91% | 34 |
|
|
2020
Q1 | $79.3M | Buy |
+1,261,257
| New | +$91M | 0.85% | 31 |
|
|
2019
Q4 | – | Sell |
-951,249
| Closed | -$69.7M | – | 704 |
|
|
2019
Q3 | $69.7M | Buy |
+951,249
| New | +$66.8M | 0.72% | 42 |
|
|
2018
Q4 | – | Sell |
-6,801
| Closed | -$395K | – | 700 |
|
|
2018
Q3 | $395K | Buy |
+6,801
| New | +$333K | 0.01% | 595 |
|
|
2018
Q1 | – | Sell |
-25,284
| Closed | -$950K | – | 597 |
|
|
2017
Q4 | $950K | Buy |
+25,284
| New | +$928K | 0.02% | 163 |
|
Other funds holding EW
VCM
VPM
Holocene Advisors's EW Position: Q1 2026 in Review
Holocene Advisors reduced its Edwards Lifesciences (EW) stake by 67% in Q1 2026, selling an estimated $125M and leaving 738,099 shares worth $59.1M. The position accounts for 0.14% of the portfolio, ranked #169.
Holocene Advisors first reported a position in EW in Q4 2017 and has held it in 27 quarters since. The position peaked at $369M in Q3 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Holocene Advisors held 738,099 shares of Edwards Lifesciences worth $59.1M as of Q1 2026.
- Holocene Advisors sold 1,512,944 Edwards Lifesciences shares in Q1 2026, an estimated $125M.
- Edwards Lifesciences made up 0.14% of Holocene Advisors's portfolio in Q1 2026, its #169 holding.
- Holocene Advisors first reported a position in Edwards Lifesciences in Q4 2017 and has held it in 27 quarters since.
- Holocene Advisors's Edwards Lifesciences position peaked at $369M in Q3 2025.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.